Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Aged ≥60 Years Treated with a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study (NCT02172872)
Adriano Venditti(University of Rome Tor Vergata), Francesco Buccisano(University of Rome Tor Vergata), Anna Candoni(University of Udine), Mario Luppi(University of Modena and Reggio Emilia), Robin Foà(Sapienza University of Rome), Eliana Zuffa(Ospedale "Santa Maria delle Croci" di Ravenna), Nicola Cascavilla, Attilio Olivieri(Ospedali Riuniti di Ancona), Michal Kiciński(European Organisation for Research and Treatment of Cancer), Andrea Mengarelli(Istituti di Ricovero e Cura a Carattere Scientifico), Agostino Tafuri(Azienda Ospedaliera Sant'Andrea), Maria Ilaria Del Principe(University of Rome Tor Vergata), Michael Lübbert(University of Freiburg), Annalisa Imovilli(Azienda Sanitaria Unità Locale di Reggio Emilia), Paolo de Fabritiis(St. Eugenio Hospital), Marco Vignetti(Fondazione Gimema Onlus), Stefan Suciu(St James's University Hospital), Ernesta Audisio(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Geert A. Huls(University Medical Center Groningen), Maurizio Musso(La Maddalena), Pierre W. Wijermans(Radboud University Nijmegen), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Stéphanie Antunes(European Organisation for Research and Treatment of Cancer)
Cited by 1
Related Papers
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k